Regeneron Reports IDMC Clearance of Efficacy for REGEN-COV (Casirivimab + Imdevimab) in P-III COVID-19 Outpatient Outcomes Trial

February 26, 2021 Auto Bot P-III, Regeneron, regulatory, reports, Trial 0

Shots:

  • Regeneron reported changes to the P-III study assessing REGEN-COV in non-hospitalized patients with COVID-19, following recommendations from the IDMC
  • The IDMC found clear clinical efficacy in reducing the rate of hospitalization and death with both doses (1,200 & 2,400 mg) of REGEN-COV vs PBO. The company will immediately stop enrolling patients in the PBO group, following the IDMC’s recommendation
  • The trial will continue to enroll patients in both treatment arms. IDMC has also reassured that REGEN-COV effectively neutralizes emerging strains of the virus in its preclinical data

Click here ­to­ read full press release/ article | Ref: Regeneron | Image: The Print

The post Regeneron Reports IDMC Clearance of Efficacy for REGEN-COV (Casirivimab + Imdevimab) in P-III COVID-19 Outpatient Outcomes Trial first appeared on PharmaShots.